| New treatment modalities in osteoporosis. | |
| | |
MedLine Citation:
|
PMID: 20350910 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To describe recently discovered agents for the management of osteoporosis. METHODS: A literature review (PubMed search) was conducted to identify agents at various stages of development for osteoporosis treatment. Agents under study or review for approval were included. RESULTS: In menopause, bone remodeling is increased, and agents that suppress bone resorption can stabilize bone mass. In contrast, agents that target the osteoblast can increase bone formation and bone mass. Novel antiresorptive agents can target the formation or the activity of osteoclasts. They include denosumab, an antibody to receptor activated nuclear factor κB; new selective estrogen receptor modulators, such as bazedoxifene; and cathepsin K inhibitors, such as odanacatib. Src kinase inhibitors are in the early phases of development. Parathyroid hormone is the only approved anabolic agent for the treatment of osteoporosis. Novel anabolic therapies for osteoporosis may include the use of factors with anabolic properties for bone or the neutralization of growth factor antagonists. Recent discoveries have demonstrated that the Wnt/β-catenin signaling pathway has a central role in osteoblastic cell differentiation. Antibodies to Wnt antagonists, such as sclerostin, are under development as new therapeutic approaches for osteoporosis. Anabolic therapies have the potential to enhance bone mass, but their long-term safety must be proven. CONCLUSIONS: New developments in the treatment of osteoporosis include novel antiresorptive and anabolic agents. Their success will depend on their long-term effectiveness and safety profile. |
| | |
Authors:
|
Ernesto Canalis |
Publication Detail:
|
Type: Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Review |
Journal Detail:
|
Title: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists Volume: 16 ISSN: 1934-2403 ISO Abbreviation: Endocr Pract Publication Date: 2010 Sep-Oct |
Date Detail:
|
Created Date: 2011-03-01 Completed Date: 2011-06-21 Revised Date: 2012-02-16 |
Medline Journal Info:
|
Nlm Unique ID: 9607439 Medline TA: Endocr Pract Country: United States |
Other Details:
|
Languages: eng Pagination: 855-63 Citation Subset: IM |
Affiliation:
|
Department of Research, Saint Francis Hospital and Medical Center, Hartford, Connecticut 06105-1299 , USA. ecanalis@stfranciscare.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anabolic Agents
/
therapeutic use Bone Density Conservation Agents / therapeutic use Combined Modality Therapy / methods, trends Drugs, Investigational / therapeutic use Female Humans Osteoporosis / therapy* Osteoporosis, Postmenopausal / therapy Selective Estrogen Receptor Modulators / therapeutic use Therapies, Investigational / methods, trends* |
| Grant Support | |
ID/Acronym/Agency:
|
AR021707/AR/NIAMS NIH HHS; DK042424/DK/NIDDK NIH HHS; DK045227/DK/NIDDK NIH HHS; R01 AR021707-30/AR/NIAMS NIH HHS; R01 DK042424-18/DK/NIDDK NIH HHS; R01 DK045227-18/DK/NIDDK NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anabolic Agents; 0/Bone Density Conservation Agents; 0/Drugs, Investigational; 0/Selective Estrogen Receptor Modulators |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: American association of clinical endocrinologists protocol for standardized production of clinical p...
Next Document: Impaired postoperative hyperglycemic stress response associated with increased mortality in patients...